MetaCap

Artiva Biotherapeutics (ARTV) vs Inhibikase Therapeutics (IKT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Artiva Biotherapeutics (ARTV) has outperformed Inhibikase Therapeutics (IKT) over the past year, gaining 20.8% versus a loss of 11.4%. Artiva Biotherapeutics is the larger company by market cap ($186.9 million vs $185.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARTV+20.77%IKT-11.41%
+345%+158%-30%
Nov 21, 20251 yearNov 20, 2026
ARTV-68.50%IKT-12.00%
+140%+21%-99%
Jul 15, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARTV versus IKT key metrics
MetricARTVIKT
Share price$3.78$1.32
Market cap$186.85M$185.16M
1-day change-1.31%+1.54%
YTD return-11.89%-35.61%
1-year return+20.77%-11.41%
5-year return—-89.32%
EPS (TTM)$-2.85$-0.40
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-83.86M$-48.26M
52-week high$14.53$2.61
52-week low$2.96$1.28
Distance from 52-week high-73.98%-49.43%
Analyst consensusbuystrong_buy
Avg. price target upside+448.94%+320.45%
Average volume792.26K584.27K
Shares outstanding49.43M140.27M
Employees13435
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ARTV has outperformed IKT by 32.2 percentage points over the past year.

About Artiva Biotherapeutics

ARTV stock →

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees

About Inhibikase Therapeutics

IKT stock →

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees

ARTV vs IKT FAQ

Which is bigger, Artiva Biotherapeutics or Inhibikase Therapeutics?

Artiva Biotherapeutics (ARTV) is larger, with a market capitalization of $186.85M compared with $185.16M for Inhibikase Therapeutics (IKT).

Which stock has performed better over the past year, ARTV or IKT?

ARTV returned +20.77% over the past 12 months, compared with -11.41% for IKT (price return, excluding dividends). Past performance does not predict future results.

Are Artiva Biotherapeutics and Inhibikase Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons